Recently, the U.S. Food and Drug Administration (FDA) has approved the cathepsin-activatable imaging agent pegulicianine (also known as Lumisight or LUM015) in adults with breast cancer to assist in the detection of cancerous tissue during BCS [12, 13]. This evidence concerns the gene CTSS and breast carcinoma.